MXPA02011431A - Composiciones y metodos para usar contra la inflamacion inducida por acne y enzimas que degradan la matriz dermica. - Google Patents

Composiciones y metodos para usar contra la inflamacion inducida por acne y enzimas que degradan la matriz dermica.

Info

Publication number
MXPA02011431A
MXPA02011431A MXPA02011431A MXPA02011431A MXPA02011431A MX PA02011431 A MXPA02011431 A MX PA02011431A MX PA02011431 A MXPA02011431 A MX PA02011431A MX PA02011431 A MXPA02011431 A MX PA02011431A MX PA02011431 A MXPA02011431 A MX PA02011431A
Authority
MX
Mexico
Prior art keywords
compositions
methods
degrading enzymes
induced inflammation
use against
Prior art date
Application number
MXPA02011431A
Other languages
English (en)
Inventor
Gary J Fisher
Original Assignee
Univ Michigan
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Michigan filed Critical Univ Michigan
Publication of MXPA02011431A publication Critical patent/MXPA02011431A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/07—Retinol compounds, e.g. vitamin A
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/19—Cosmetics or similar toiletry preparations characterised by the composition containing inorganic ingredients
    • A61K8/22—Peroxides; Oxygen; Ozone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/67—Vitamins
    • A61K8/671—Vitamin A; Derivatives thereof, e.g. ester of vitamin A acid, ester of retinol, retinol, retinal
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/10—Anti-acne agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/06—Free radical scavengers or antioxidants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
    • A61P5/44—Glucocorticosteroids; Drugs increasing or potentiating the activity of glucocorticosteroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
    • A61K2800/74—Biological properties of particular ingredients
    • A61K2800/78—Enzyme modulators, e.g. Enzyme agonists
    • A61K2800/782—Enzyme inhibitors; Enzyme antagonists

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Birds (AREA)
  • Dermatology (AREA)
  • Inorganic Chemistry (AREA)
  • Emergency Medicine (AREA)
  • Toxicology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Endocrinology (AREA)
  • Diabetes (AREA)
  • Biochemistry (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
MXPA02011431A 2000-05-22 2001-05-22 Composiciones y metodos para usar contra la inflamacion inducida por acne y enzimas que degradan la matriz dermica. MXPA02011431A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US57659700A 2000-05-22 2000-05-22
US09/852,154 US20040235950A1 (en) 1999-05-20 2001-05-09 Compositions and methods for use against acne-induced inflammation and dermal matrix-degrading enzymes
PCT/US2001/016537 WO2001089502A2 (en) 2000-05-22 2001-05-22 Compositions and methods for use against acne-induced inflammation and dermal matrix-degrading enzymes

Publications (1)

Publication Number Publication Date
MXPA02011431A true MXPA02011431A (es) 2004-01-26

Family

ID=27076996

Family Applications (1)

Application Number Title Priority Date Filing Date
MXPA02011431A MXPA02011431A (es) 2000-05-22 2001-05-22 Composiciones y metodos para usar contra la inflamacion inducida por acne y enzimas que degradan la matriz dermica.

Country Status (7)

Country Link
US (2) US20040235950A1 (es)
EP (1) EP1284721A2 (es)
JP (1) JP2004515460A (es)
AU (1) AU2001271266A1 (es)
CA (1) CA2409929A1 (es)
MX (1) MXPA02011431A (es)
WO (1) WO2001089502A2 (es)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050033251A1 (en) * 1998-12-08 2005-02-10 Quick-Med Technologies, Inc. Controlled release of biologically active substances from select substrates
DE10127432A1 (de) * 2001-06-06 2002-12-12 Beiersdorf Ag Wirkstoffkombination zur Verhinderung unerwünschter Hautpigmentierung
US20100222316A1 (en) * 2004-04-29 2010-09-02 Abbott Laboratories Inhibitors of the 11-beta-hydroxysteroid dehydrogenase type 1 enzyme
ES2474694T3 (es) * 2006-01-05 2014-07-09 Galderma Research & Development Método de diagnóstico del acné usando biomarcadores de lesiones y método de cribado in vitro para identificar sus moduladores
US20080025930A1 (en) * 2006-07-31 2008-01-31 Hugo Corstjens Anti-aging Compositions Comprising Menyanthes Trifoliata Leaf Extracts and Methods of Use Thereof
WO2008034161A1 (en) * 2006-09-19 2008-03-27 Phylogica Limited Neuroprotective peptide inhibitors of ap-1 signaling and uses therefor
WO2008053199A1 (en) * 2006-10-30 2008-05-08 Astrazeneca Ab Combination therapy for the treatment of respiratory diseases
WO2009141541A2 (fr) * 2008-04-22 2009-11-26 Centre National De La Recherche Scientifique Nouvelles compositions inhibant la melanogenese et leurs utilisations
US10179900B2 (en) * 2008-12-19 2019-01-15 DePuy Synthes Products, Inc. Conditioned media and methods of making a conditioned media
RU2012112589A (ru) * 2009-09-02 2013-10-10 Юниверсити Оф Вирджиния Пэйтент Фаундейшн Отслеживание вероятности приближающейся гипогликемии при диабете на основе данных самостоятельного контроля глюкозы в крови
US8895628B2 (en) 2010-10-25 2014-11-25 Johnson & Johnson Consumer Companies, Inc. Compositions comprising a retinoid and an NFkB-inhibitor and their methods of use
US20140086859A1 (en) 2012-09-24 2014-03-27 Johnson & Johnson Consumer Companies, Inc. Low oil compositions comprising a 4-substituted resorcinol and a high carbon chain ester
RU2015156254A (ru) * 2014-05-07 2017-07-04 Конинклейке Филипс Н.В. Устройство, система и способ выделения физиологической информации
US10058542B1 (en) 2014-09-12 2018-08-28 Thioredoxin Systems Ab Composition comprising selenazol or thiazolone derivatives and silver and method of treatment therewith
KR20200063798A (ko) * 2018-11-28 2020-06-05 박정혜 퀘르세틴, 제니스테인 및 알파리포산을 함유하는 여드름 피부 개선용 조성물
WO2023068233A1 (ja) * 2021-10-18 2023-04-27 マルホ株式会社 活性阻害及び／又は産生抑制剤

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4005198A (en) * 1975-09-12 1977-01-25 Robert H. Van Aman Treatment of acne vulgaris
US4219548A (en) * 1978-09-01 1980-08-26 The Procter & Gamble Company Topical anti-inflammatory composition
US4942031A (en) * 1988-02-23 1990-07-17 Levin Robert H Compositions containing LYCD and other topically active medicinal ingredients
LU87410A1 (fr) * 1988-12-20 1990-07-10 Cird Composition cosmetique ou pharmaceutique contenant des microspheres de polymeres ou de corps gras chargees d'au moins un produit actif
EP0614353A1 (en) * 1991-11-25 1994-09-14 Richardson-Vicks, Inc. Compositions for regulating skin wrinkles and/or skin atrophy
DE4218572A1 (de) * 1992-06-05 1993-12-09 Asta Medica Ag Synergistische Kombination von Arzneimitteln enthaltend als Wirkstoff alpha-Liponsäure, Dihydroliponsäure, deren Metaboliten sowie die oxidierten und reduzierten Enantiomere der alpha-Liponsäure wie die R-alpha-Liponsäure oder S-alpha-Liponsäure sowie Metaboliten der alpha-Liponsäure mit den Vitaminen A, B1-6, B12, C und E
US5460620A (en) * 1992-07-31 1995-10-24 Creative Products Resource, Inc. Method of applying in-tandem applicator pads for transdermal delivery of a therapeutic agent
FR2694934B1 (fr) * 1992-08-24 1994-11-10 Oreal Composition pour le traitement de l'acné contenant un dérivé d'acide salicylique et dérivés d'acide salicylique.
WO1994022309A1 (en) * 1993-04-07 1994-10-13 Glycomed Incorporated Synthetic matrix metalloprotease inhibitors and uses thereof
FR2715565B1 (fr) * 1994-01-31 1996-03-15 Oreal Composition cosmétique ou dermatologique stabilisée contenant plusieurs précurseurs d'un même actif pour maximaliser sa libération, son utilisation.
GB9405076D0 (en) * 1994-03-16 1994-04-27 Inst Of Ophtalmology A medical use of matrix metalloproteinase inhibitors
CZ385896A3 (en) * 1994-07-01 1997-08-13 Procter & Gamble Desquamation preparations
US5445823A (en) * 1994-10-20 1995-08-29 The Procter & Gamble Company Dermatological compositions and method of treatment of skin lesions therewith
DE4444238A1 (de) * 1994-12-13 1996-06-20 Beiersdorf Ag Kosmetische oder dermatologische Wirkstoffkombinationen aus Zimtsäurederivaten und Flavonglycosiden
US5652227A (en) * 1995-01-30 1997-07-29 Teronen; Olli Pekka Inhibition of the degradation of connective tissue matrix protein components in mammals
US5643623A (en) * 1995-06-07 1997-07-01 Mars Incorporated Health food product and its uses
US6218128B1 (en) * 1997-09-12 2001-04-17 Allergan Sales, Inc. Methods of identifying compounds having nuclear receptor negative hormone and/or antagonist activities
US5837224A (en) * 1996-01-19 1998-11-17 The Regents Of The University Of Michigan Method of inhibiting photoaging of skin
US5741896A (en) * 1996-06-21 1998-04-21 Allergan O- or S- substituted tetrahydronaphthalene derivatives having retinoid and/or retinoid antagonist-like biological activity
DE19632840A1 (de) * 1996-08-14 1998-02-19 Landsberger Albert Vitamin A-haltige Zusammensetzung
US5665367A (en) * 1996-09-27 1997-09-09 Chesebrough-Pond's Usa Co., Division Of Conopco, Inc. Skin care compositions containing naringenin and/or quercetin and a retinoid
US5739338A (en) * 1996-11-05 1998-04-14 Allergan N-aryl substituted tetrahydroquinolines having retinoid agonist, retinoid antagonist or retinoid inverse agonist type biological activity
US5728846A (en) * 1996-12-12 1998-03-17 Allergan Benzo 1,2-g!-chrom-3-ene and benzo 1,2-g!-thiochrom-3-ene derivatives
US5804594A (en) * 1997-01-22 1998-09-08 Murad; Howard Pharmaceutical compositions and methods for improving wrinkles and other skin conditions
US5962030A (en) * 1997-03-07 1999-10-05 Akesis Pharmaceuticals, Inc. Dietary supplement and method of treatment for diabetic control
WO1998050348A1 (en) * 1997-05-09 1998-11-12 Agouron Pharmaceuticals, Inc. Metalloproteinase inhibitors, pharmaceutical compositions containing them and their pharmaceutical uses
TWI234467B (en) * 1997-06-04 2005-06-21 Univ Michigan Composition for inhibiting photoaging of skin
CA2302017C (en) * 1997-08-25 2007-01-30 Harold Brem Prevention of adhesions and excessive scar formation using angiogenesis inhibitors

Also Published As

Publication number Publication date
CA2409929A1 (en) 2001-11-29
EP1284721A2 (en) 2003-02-26
US20060009494A1 (en) 2006-01-12
US20040235950A1 (en) 2004-11-25
WO2001089502A2 (en) 2001-11-29
JP2004515460A (ja) 2004-05-27
WO2001089502A3 (en) 2003-01-03
AU2001271266A1 (en) 2001-12-03

Similar Documents

Publication Publication Date Title
AU2001265008A1 (en) Caspase inhibitors and uses thereof
WO2002017157A8 (en) Marketing systems and methods
MXPA02011431A (es) Composiciones y metodos para usar contra la inflamacion inducida por acne y enzimas que degradan la matriz dermica.
AU2001219651A1 (en) Mulch composition and method
AU3731400A (en) Methods and compositions useful in inhibiting apoptosis
AU2001286651A1 (en) Microparticle composition and method
AU1812001A (en) Cotton transcription factors and their uses
AU2001264258A1 (en) Nonwoven-fabric laminate and use thereof
AU2001233951A1 (en) Improvements in and relating to active noise reduction
AU2002211717A1 (en) Stresscopins and their uses
AU2001292936A1 (en) Octahydro-indolizines and quinolizines and hexahydro-pyrrolizines
AU2001229439A1 (en) Bioconjugates and uses thereof
AU2001261750A1 (en) Laminate and its use
AU2001241498A1 (en) Matrix metalloproteinase inhibitors and uses thereof
AU2001295185A1 (en) Multiplexing-interleaving and demultiplexing-deinterleaving
AU2001233932A1 (en) Method and composition
AU4426801A (en) Composition based on sphingolipid and beta-hydroxy-acid for skin care
AU2001237592A1 (en) Enzymes and uses relating thereto
AU2002239775A1 (en) Chemical-library composition and method
AU2002227019A1 (en) Cashcalling and voicemining system
AU2001252062A1 (en) Steatosis-modulating factors and uses thereof
AU4455201A (en) Hyaluronidase activity and allergenic cell activity inhibitor
AU2002256556A1 (en) Sea-trosy and related methods
AU7448401A (en) Method to regenerate plants and uses thereof to multiply and/or transform plants
AU2001269203A1 (en) Micro-organisms active in the digestive environment

Legal Events

Date Code Title Description
FA Abandonment or withdrawal